When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.

The Saudi Food and Drug Authority (SFDA) has approved a clinical study to evaluate the safety and pharmacokinetics of an ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a ...

The company's pending vaccine approvals could help the stock continue its rise.

Provides broad overview of Company's research and early development programs expected to continue to fuel future growth ...

Provides broad overview of Company's research and early development programs expected to continue to fuel future growthHighlights validation of T-cell engager modality with mRNA-2808 in multiple myelo ...

Moderna appointed a new chief commercial officer and widened its president's role to oversee certain franchises, ​the vaccine maker said on Tuesday, as it ‌prepares for potential product launches over ...

Dr. Stephen Hoge, President of Moderna, to Assume an Expanded Role With Operational Oversight of the Company's Infectious Disease, Intismeran and Rare Disease Franchises ...

The Horizon programme contains a variety of mRNA assets in varying stages of development, including a preclinical in vivo ...

A set of 31 YACs, potentially residing in 3q22–q23, was directly derived from the information available in the public databases. The YAC clones were obtained from CEPH (Paris). Their chromosomal ...

Shares of Moderna MRNA rose nearly 13% on Friday after the company unveiled a long-term strategy to transform itself from a ...

Key Points Interested in Moderna, Inc.? Here are five stocks we like better. Moderna shares rose nearly 20% after Science Day ...